Helen Burstin, MD, MPH, FACP, chief scientific officer of The National Quality Forum, explained that the 2 gaps that exist in quality measurement currently include data infrastructure and patient engagement.
Helen Burstin, MD, MPH, FACP, chief scientific officer of The National Quality Forum, explained that the 2 gaps that exist in quality measurement currently include data infrastructure and patient engagement.
Transcript (slightly modified)
Where is one of the biggest gaps in quality measurement right now?
For example, care coordination measurement. We all know it’s important. We’ve all identified it as something that is kind of a lynch pin in our efforts to move the system forward. It is very, very difficult currently to get at good care coordination measures. We don’t have the data infrastructure currently with interoperable systems to allow us to look across systems.
We are beginning to rely on the voice of the patient, which is wonderful in terms of 1, input into asking patients and their families for example about how well coordinated care was. But, as you think about trying to get towards value, things like care coordination and other key areas like end-of-life care, adverse medical events, so many of the big issues that we know drive both adverse patient effects but also higher costs are some of the issues we’re trying to get our arms around.
How do gaps in quality measurements occur?
There are a couple of different reasons. I think first, certainly, not having available data is a pretty significant piece of it. I think that’s what’s driven some of the gaps around care coordination, for example.
I do think secondly, and one of the things we’ve learned as part of this new work we’re doing around this measure incubator and our desire to launch this measure’s collaborative is that a rate limiting step for many measure developers, even if they come up with a great, new innovative measures, are the test beds aren’t there to test the measure. So again, we’re trying to think about how we can do that.
I think the third thing for some of these measures that are specially patient-centered, we don’t have enough patient engagement through the measure development process. So we’re trying to think about ways to ensure that from the start of measure development, you’ve got significant patient representation and their voices heard all the way through the process and secondly, you’ve got data all the way through the process. So you can really be much more agile and create a better measure.
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More